Laboratorios Farmaceuticos Rovi SA 2025 SR
The report outlines Laboratorios Farmacéuticos Rovi's sustainability performance and strategic progress for the fiscal year 2025. Key highlights include the approval of the new ESG Master Plan 2026-2030, which establishes a clear roadmap for decarbonization and social impact. The company successfully reduced its Scope 1 and Scope 3 greenhouse gas emissions and increased its renewable energy self-consumption to 10.46%. Additionally, ROVI expanded its contract manufacturing capabilities and advanced its innovative drug-delivery technology, Okedi, across several European markets.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2025
Type: SR
Pages: 198
Back to company
Laboratorios Farmaceuticos Rovi SA
Non-Financial Information Statement And Sustainability Reporting
The report outlines Laboratorios Farmacéuticos Rovi's sustainability performance and strategic progress for the fiscal year 2025. Key highlights include the approval of the new ESG Master Plan 2026-2030, which establishes a clear roadmap for decarbonization and social impact. The company successfully reduced its Scope 1 and Scope 3 greenhouse gas emissions and increased its renewable energy self-consumption to 10.46%. Additionally, ROVI expanded its contract manufacturing capabilities and advanced its innovative drug-delivery technology, Okedi, across several European markets.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees